Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Focus on Celldex Therapeutics (CLDX) Data from ASCO

|Includes: Celldex Therapeutics, Inc (CLDX), CYTR, PCYC

Below is a short list of the latest updates at, a biotechnology and pharmaceutical database that allows institutional and retail investors, analysts, traders, consultants, executives, and professionals to track relevant industry information.  As of June 2010, the database covers over 290 publicly-traded biotechnology and pharmaceutical companies, more than 1000 profiles of approved and development-stage drugs, devices and diagnostics, and 17 different catalyst types.

Celldex Therapeutics (NASDAQ:CLDX)

We've added the latest ASCO data, including the latest CDX-110 GBM results, CDX-011 breast cancer and melanoma results, and the bladder cancer design for CDX-1307.  We're also expecting final data from the ACT III trial in 4Q10.

More on CLDX data at Taragana, Bullfax, and BioHealth Business Daily.

Pharmacyclics (NASDAQ:PCYC)

Data presented over the weekend from PCYC's BTK inhibitor, PCI-32765, has been updated.  Read more at EnterprisePost.

June 7 Updates

The latest news for CytRx (NASDAQ:CYTR) and Harbor Biosciences (OTCPK:HRBR).

Disclosure: No positions